上海交通大学学报(医学版)

• 论著(临床研究) • 上一篇    下一篇

伊马替尼治疗儿童慢性髓细胞性白血病效果分析

李珊珊,蒋 慧   

  1. 上海交通大学附属儿童医院, 上海市儿童医院血液肿瘤科, 上海 200040
  • 出版日期:2015-01-28 发布日期:2015-01-29
  • 通讯作者: 蒋 慧, 电子信箱: jhui0111@126.com。
  • 作者简介:李珊珊(1988—), 女, 硕士生; 电子信箱: jtsdlishanshan@163.com。

Therapeutic effect of imatinib on children with chronic myelogenous leukemia

LI Shan-shan, JIANG Hui   

  1. Department of Hematology and Oncology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai 200040, China
  • Online:2015-01-28 Published:2015-01-29

摘要:

目的 回顾性分析伊马替尼对儿童慢性髓细胞性白血病的疗效及不良反应。方法 收集2012年1月—2013年1月经MICM分型标准确诊为慢性髓细胞性白血病伴费城染色体阳性且接受伊马替尼治疗患儿的临床资料。5例患儿中,男2例,女3例;中位年龄为9岁(6~11岁);均予以伊马替尼口服[340 mg/(m2·d)];中位随访时间为25个月(15~30个月),定期观察患儿临床表现及外周血象、骨髓细胞学和分子生物学指标的变化,同时监测生长发育和骨骼代谢情况。结果 经伊马替尼规范治疗后,患儿分别在3个月和12个月内获得完全血液学缓解和细胞遗传学缓解。1例患儿伊马替尼治疗25个月后血清骨钙素水平超出正常值上限1倍多,其余患儿未见生长发育相关指标明显异常。结论 伊马替尼对慢性髓细胞性白血病患儿的疗效显著且安全,其不良反应尚有待长期随访跟踪。

关键词: 慢性髓细胞性白血病, 费城染色体, 伊马替尼, 儿童

Abstract:

Objective To retrospectively analyze the therapeutic and adverse effects of imatinib (IM) on children with chronic myelogenous leukemia (CML). Methods The clinical data of 5 children who were diagnosed as CML combined with positive Philadelphia chromosome according to the MICM standard and treated with IM from Jan. 2012 to Jan. 2013 were collected. Among 5 cases, there were 2 males  and 3 females. The median age was 9 (6-11) years old. IM of 340 mg/(m2·d) was orally administrated and the median follow-up time was 25 (15-30) months. The clinical manifestations, variations of indexes of peripheral hemogram, bone marrow cytology, and molecular biology, as well as growth and development and bone metabolism were observed regularly. Results After being treated with IM, all patients attained complete hematological response (CHR) and complete cytogenetic response (CCyR) in 3 and 12 months, respectively. The serum osteocalcin level of 1 patient was one time higher than the upper limit of normal level after being treated with IM for 25 months. Indexes relevant to growth and development of other patients showed no significant abnormalities. Conclusion The therapeutic effect of IM on children with CML is significant and safe and the adverse effects should be observed through the long-term follow-up.

Key words: chronic myeloid leukemia, Philadelphia chromosome, imatinib, children